A new combination therapy has led to an exceptionally long survival in a dog diagnosed with a rare and aggressive form of bone cancer, according to a recent case report. The treatment, which paired a cutting-edge oncolytic virus with standard amputation and chemotherapy, resulted in the dog surviving over seven years and remaining alive at the time of publication.
Hemangiosarcoma originating in the bone is an uncommon cancer in dogs, with a median survival time of less than 10 months even with aggressive treatment involving amputation and chemotherapy. This case report details the treatment of a five-year-old mixed-breed dog initially suspected to have osteosarcoma. As part of a clinical trial, the dog received a single intravenous dose of an oncolytic virus—a genetically modified vesicular stomatitis virus (VSV-IFNβ-NIS)—designed to infect and destroy cancer cells while stimulating the immune system.
Ten days after the virus therapy, the affected limb was amputated. A detailed analysis of the tumor post-amputation revealed a surprise: the diagnosis was revised to primary intramedullary hemangiosarcoma. This distinction is critical, as the two cancers can appear similar but require different chemotherapy protocols. Following the revised diagnosis, the dog received a standard chemotherapy drug, doxorubicin, instead of the originally planned drug.
Key findings and implications from this case include:
- Extended Survival: The dog achieved a remarkable survival of more than seven years following diagnosis. This drastically exceeds the typical survival for canine bone HSA and suggests the potential for a powerful treatment effect from the combination therapy.
- Role of the Oncolytic Virus: While the individual contribution of the virus cannot be proven in a single case, researchers hypothesize it may have initiated a potent anti-tumor immune response that helped control the cancer long-term. The study notes this is the first documented case of a dog with bone HSA being treated with this type of virotherapy.
- Importance of Accurate Diagnosis: The case highlights the challenge of differentiating between certain bone cancers. The definitive diagnosis of HSA was only confirmed after amputation using specialized stains (CD31 and Factor VIII), underscoring the need for advanced diagnostic techniques to guide appropriate treatment.
- A Multi-Modal Approach is Key: The success in this dog is attributed to the combination of novel immunotherapy (the virus), local disease control (amputation), and systemic treatment (chemotherapy). It is unclear if any one component alone would have yielded the same result.
Although this report involves only a single dog, it provides a strong foundation for future research. The extraordinary outcome warrants further investigation into oncolytic virotherapy as a potential new weapon against highly aggressive cancers like hemangiosarcoma. Future clinical trials will be necessary to determine the safety and efficacy of this approach in a larger group of dogs.
